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  S
ince the early 1970s, when 
cannabis ﬁ  rst began to be 
widely used [1], the proportion 
of young people who have used 
cannabis has steeply increased and 
the age of ﬁ  rst use has declined [2,3]. 
Most cannabis users now start in the 
mid-to-late teens [1], an important 
period of psychosocial transition 
when misadventures can have large 
adverse effects on a young person’s life 
chances. 
    Dependence is an underappreciated 
risk of cannabis use [1]. There has 
been an increase in the numbers of 
adults requesting help to stop using 
cannabis in many developed countries, 
including Australia [4] and the 
Netherlands [1,5]. Regular cannabis 
users develop tolerance to many of the 
effects of delta-9-tetrahydrocannabinol 
[6–8], and those seeking help to stop 
often report withdrawal symptoms [9-
11]. Withdrawal symptoms have been 
reported by 80% of male and 60% of 
female adolescents seeking treatment 
for cannabis dependence [12,13]. 
    In epidemiological studies in the 
early 1980s [14] and 1990s [15], it was 
found that 4% of the United States 
population had met diagnostic criteria 
for cannabis abuse or dependence 
at some time in their lives. Surveys in 
Australia, Canada, and New Zealand 
have produced similar estimates [16–
19]. About one in ten of those who use 
cannabis meet criteria for dependence 
[15], but this risk is much higher 
for daily users and persons who start 
using at an early age [20,21]. Only a 
minority of cannabis-dependent people 
in surveys report seeking treatment 
(Chapter 7 of [1]), but among those 
who do, fewer than half succeed in 
remaining abstinent for as long as a 
year [9,10,22].
    Those who use cannabis more 
often than weekly in adolescence are 
more likely to develop dependence, 
use other illicit drugs, and develop 
psychotic symptoms and psychosis 
[1]. Establishing whether cannabis 
use is a contributory cause of these 
outcomes [1] requires two things: (1) 
longitudinal research on the effects 
that cannabis use in adolescence has 
on psychosocial outcomes in young 
adulthood [23], and (2) statistical 
methods to control for the fact that 
young people who regularly use 
cannabis differ from their peers who 
do not in ways that increase regular 
cannabis users’ risk of these adverse 
psychosocial outcomes [1,23].
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    Is Cannabis a Gateway Drug?
    Surveys of adolescents in the United 
States over the past 30 years have 
consistently shown [24] that: (1) almost 
all adolescents who had tried cocaine 
and heroin had ﬁ  rst used alcohol, 
tobacco, and cannabis, in that order 
[25,26], (2) regular cannabis users 
are the most likely to use heroin and 
cocaine [27], and (3) the earlier the 
age of ﬁ  rst cannabis use, the more 
likely a young person is to use other 
illicit drugs [26]. 
    Three explanations have been offered 
for these patterns: that those who use 
cannabis at an early age are more likely 
for other reasons to use other illicit 
drugs; that cannabis users obtain the 
drug from the same black market as 
other illicit drugs (providing more 
opportunities to use these drugs); and 
that the effects of cannabis on the brain 
increase an adolescent’s propensity to 
use other illicit drugs [28]. 
    Animal studies of the neurobiology 
of drug effects provide some 
biological plausibility for a causal 
relationship in showing that cannabis 
and other illicit drugs act on the 
same brain reward centres [29–31]. 
Nevertheless, the role that cannabis 
plays remains controversial because it 
is difﬁ  cult to exclude the hypothesis 
that these patterns of use are 
substantially explained by the personal 
characteristics of cannabis users and 
the shared environments that make 
those who use cannabis more likely to 
use other drugs [24,32]. 
    Several studies have recently 
suggested that the pattern cannot be 
wholly explained in this way. A well-
controlled longitudinal study of a birth 
cohort found that the pattern did not 
disappear after statistical adjustment 
for plausible common factors [33]. Two 
studies of twins who were discordant 
for cannabis use have found that the 
relationship between cannabis use and 
the use of other illicit drugs persisted 
after controlling for the effects of 
shared genes and environment [34,35]. 
    Cannabis Use and Psychosis 
    Cannabis use and psychotic symptoms 
and disorders are associated in the 
population [37–38] and in persons 
with schizophrenia [39–41]. The 
major explanations of this association 
have been that: (1) cannabis use 
precipitates schizophrenia in persons 
who are vulnerable to the disorder [1], 
(2) cannabis is used to self-medicate 
symptoms of schizophrenia, or (3) the 
association arises from uncontrolled 
confounding by variables that predict 
an increased risk of both cannabis use 
and schizophrenia [23,42]. 
    The ﬁ  rst explanation was supported 
by a 15-year prospective study of 50,465 
Swedish conscripts [43] that found a 
dose–response relationship between the 
risk of developing schizophrenia and 
the number of times cannabis had been 
used by age 18. These risks remained 
signiﬁ  cant after statistical adjustment 
for confounding variables. A later 27-
year follow-up of this cohort [44] also 
found a dose–response relationship 
between the frequency of cannabis use 
and the risk of schizophrenia, which 
persisted after statistically controlling for 
confounding factors. 
    These ﬁ  ndings have been recently 
replicated in: a three-year study of 
4,848 young people in the Netherlands 
[45]; a 4-year follow up of a cohort of 
2,437 young Germans [46]; and two 
New Zealand birth cohorts (  n   = 759 
[47];   n   = 900 [48]). All of these studies 
found a relationship between regular 
cannabis use and psychosis (with a RR 
of 2–3) that persisted after controlling 
for confounding variables [49].
    In the Dutch, German and New 
Zealand cohorts, young people who 
reported psychotic symptoms at 
baseline were much more likely to 
report psychotic symptoms at follow-
up if they used cannabis than were 
cannabis-using peers who did not 
report these symptoms at baseline. In 
one of the New Zealand studies, young 
people with a variant allele of the 
COMT gene who used cannabis had a 
risk of reporting psychotic symptoms 
that was ten times higher than young 
people who did not have the allele who 
used cannabis [50]. 
    The self-medication hypothesis 
was not supported in the van Os or 
Henquet studies [45,46], both of 
which found that early psychotic 
symptoms did not predict an increased 
use of cannabis. These results have 
been supported by Verdoux et al. 
[51], who found that cannabis users 
were more likely to report unusual 
perceptions after using cannabis than 
to report using cannabis in response to 
experiencing unusual perceptions, and 
that this relationship was stronger in 
individuals with a history of psychotic 
experiences. 
  Communicating  the  Risks 
    In most developed countries, the 
debate about cannabis policy is often 
simpliﬁ  ed to a choice between two 
options: (1) to legalize cannabis 
because its use is harmless, or (2) to 
continue to prohibit its use because 
it is harmful [1]. As a consequence, 
evidence that cannabis use causes 
harm to adolescents is embraced by 
supporters of cannabis prohibition and 
is dismissed as “ﬂ  awed” by proponents 
of cannabis liberalization (e.g., [52]). 
    A major challenge in providing 
credible health education to young 
people about the risks of cannabis use 
is in presenting the information in a 
persuasive way that accurately reﬂ  ects 
the remaining uncertainties about 
these risks. The question of how best 
to provide this information to young 
people requires research on their 
views about these issues and the type of 
information they ﬁ  nd most persuasive. 
It is clear from US experience that it 
is worth trying to change adolescent 
views about the health risks of cannabis; 
a sustained decline in cannabis use 
during the 1980s was preceded by 
increases in the perceived risks of 
cannabis use among young people 
[53].
    The following are brief summaries 
of the evidence intended for health 
professionals. 
      Cannabis dependence.   Cannabis 
users can become dependent on 
cannabis. The risk (around 10%) is 
lower than that for alcohol, nicotine, 
and opiates, but the earlier the age a 
young person begins to use cannabis, 
the higher the risk.
      Cannabis and other illicit drug use.   
Regular users of cannabis are more 
likely to use heroin, cocaine, or other 
drugs, but the reasons for this remain 
unclear. Some of the relationship is 
attributable to the fact that young 
people who become regular cannabis 
users are more likely to use other illicit 
drugs for other reasons, and that they 
are in social environments that provide 
more opportunities to use these drugs. 
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It is worth trying 
to change adolescent 
views about the health 
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It is also possible that regular cannabis 
use produces changes in brain function 
that make the use of other drugs more 
attractive. The most likely explanation 
of the association between cannabis 
and the use of other illicit drugs 
probably involves a combination of 
these factors.
      Cannabis and psychosis.   As a rule of 
thumb, adolescents who use cannabis 
more than weekly probably increase 
their risk of experiencing psychotic 
symptoms and developing psychosis 
if they are vulnerable—if they have 
a family member with a psychosis or 
other mental disorder, or have already 
had unusual psychological experiences 
after using cannabis. This vulnerability 
may prove to be genetically mediated.   
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